Accelerating Clinical Trials - Improving Clinical Trials with Innovative Solutions
Drug developers face pressure to accelerate clinical trials to reduce costs while meeting unmet medical needs. In this video series, PPD’s industry scientists share how to improve clinical trials using innovative data solutions within the central lab, real-time data integration, technology and advancements in decentralized clinical trials (DCTs).The first video of the series has Olivia Aspite, executive director, PPD® Laboratory services, and Bryan Neth, manager, business analytics, PPD Laboratory services, discussing how the Phase III COVID-19 vaccine study provided a case study for how to improve clinical trial using innovative solutions.
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.
Flexible-Dose Development Strategies for Today's Clinical Landscape - Executive Summary
January 8th 2025This executive summary focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
